Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872217 | 0.99 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL6969799 | 0.95 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL18032527 | 0.92 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL31435518 | 0.91 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL8940284 | 0.88 | HDAC1 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL4869972 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL12815027 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL23187621 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL17825392 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL4512387 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2208726-B1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | TAKEDA PHARMACEUTICAL (JP) | 2014-08-20 | — | — | EP | disclosed |
| US-8697865-B2 | Cyclic amide derivative, and its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-15 | — | — | US | disclosed |
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| EP-2208726-A1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | Takeda Pharmaceutical Company Limited (JP) | 2010-07-21 | — | — | EP | disclosed |
| US-7745623-B2 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1748985-A1 | CYCLIC AMIDE DERIVATIVES, AND THEIR PRODUCTION AND USE AS ANTITHROMBOTIC AGENTS | Takeda Pharmaceutical Company Limited (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005113504-A1 | CYCLIC AMIDE DERIVATIVES, AND THEIR PRODUCTION AND USE AS ANTITHROMBOTIC AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | SMN1; SMN2 2741/4885NPC1 1978/4885RAB9A 4054/4885 |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | CNR1, CNR2, ARG1 | SMN1; SMN2 2828/4885NPC1 2632/4885RAB9A 3969/4885 |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, CNR2 | SMN1; SMN2 2655/4885NPC1 1762/4885RAB9A 3896/4885 |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | SMN1; SMN2 2741/4885NPC1 1978/4885RAB9A 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.